Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aakaar Medical TechnologiesNSE:AAKAAR -5.00%20 ROC (Joel Greenblatt) % is 43.33% as of Mar. 2026, which is 75% above its 10-year median of 24.78. GuruFocus rates NSE:AAKAAR with a GF Score™ of 20/100. The stock has 3 warning signs investors should review. Among 837 Medical Devices & Instruments companies, Aakaar Medical Technologies ranks better than 73.84% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Aakaar Medical Technologies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 43.33%.
The historical rank and industry rank for Aakaar Medical Technologies's ROC (Joel Greenblatt) % or its related term are showing as below:
NSE:AAKAAR'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 22.92 Med: 24.78 Max: 29.21
Current: 23.39
During the past 5 years, Aakaar Medical Technologies's highest ROC (Joel Greenblatt) % was 29.21%. The lowest was 22.92%. And the median was 24.78%.
NSE:AAKAAR's ROC (Joel Greenblatt) % is ranked better than 73.84% of 837
companies
in the Medical Devices & Instruments industry
Industry Median: 4.48
vs NSE:AAKAAR: 23.39
Aakaar Medical Technologies (NSE:AAKAAR) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aakaar Medical Technologies ROC (Joel Greenblatt) % Chart
NSE:AAKAAR vs ABT, SYK, MDT: ROC (Joel Greenblatt) % Comparison
For the Medical Devices subindustry, Aakaar Medical Technologies's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aakaar Medical Technologies ROC (Joel Greenblatt) % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Aakaar Medical Technologies's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Aakaar Medical Technologies's ROC (Joel Greenblatt) % falls into.
Aakaar Medical Technologies ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is two times the semi-annual (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 43.33% mean?
Aakaar Medical Technologies (NSE:AAKAAR) has a ROC (Joel Greenblatt) % of 43.33% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Aakaar Medical Technologies and its competitors. This is 75% above median its historical median of 24.78. Over the past decade, Aakaar Medical Technologies' ROC (Joel Greenblatt) % has ranged from 22.92 to 29.21. According to the industry distribution chart, Aakaar Medical Technologies ranks #219 out of 837 companies in the Medical Devices & Instruments industry, placing it in the top 26.2%.
Is Aakaar Medical Technologies' ROC (Joel Greenblatt) % too high?
Aakaar Medical Technologies' current ROC (Joel Greenblatt) % of 43.33% is 75% above median its 10-year median of 24.78. Over the past 10 years, this metric has ranged from a low of 22.92 to a high of 29.21. The Medical Devices & Instruments industry median ROC (Joel Greenblatt) % is 4.48. Aakaar Medical Technologies' value of 43.33% is 867.2% above this industry median. Based on the distribution chart, Aakaar Medical Technologies ranks #219 out of 837 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Aakaar Medical Technologies has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Aakaar Medical Technologies' ROC (Joel Greenblatt) % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Aakaar Medical Technologies ranks #219 out of 837 companies for ROC (Joel Greenblatt) %. This puts Aakaar Medical Technologies in the upper half of its industry. The industry median ROC (Joel Greenblatt) % is 4.48. Aakaar Medical Technologies' value of 43.33% is 867.2% above this benchmark. Historically, Aakaar Medical Technologies' own ROC (Joel Greenblatt) % has ranged from 22.92 to 29.21 over the past decade. While the company's 10-year median is 24.78 vs. the industry median of 4.48, Aakaar Medical Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median ROC (Joel Greenblatt) % among Medical Devices & Instruments companies is 4.48, based on 837 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aakaar Medical Technologies's current ROC (Joel Greenblatt) % of 43.33% is 867.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Aakaar Medical Technologies and its competitors. For the Medical Devices & Instruments industry, the median ROC (Joel Greenblatt) % is 4.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aakaar Medical Technologies's current ROC (Joel Greenblatt) % is 43.33%, which is 75% above median its own 10-year median of 24.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aakaar Medical Technologies stock overvalued right now?
Aakaar Medical Technologies (NSE:AAKAAR) has a current ROC (Joel Greenblatt) % of 43.33%. The current ROC (Joel Greenblatt) % is 43.33%, which is 75% above median its 10-year median of 24.78 and 867.2% above the Medical Devices & Instruments industry median of 4.48. Aakaar Medical Technologies' overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Aakaar Medical Technologies (NSE:AAKAAR), the current ROC (Joel Greenblatt) % is 43.33% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aakaar Medical Technologies Ltd is a medical aesthetic company dealing in a wide range of aesthetics & specialized cosmetic products & devices. Its product range includes both Own brands (domestically manufactured products & internationally manufactured devices) and Imported Brands (distribution of imported brands) from countries such as Korea, Spain, Italy, and Austria. It has established a distinctive presence in the medical aesthetic market by exclusively focusing on business-to-business(B2B) channels for product distribution and sales. The company supply its products & devices to dermatologists, plastic surgeons, aesthetic physicians who then sell these products to their end consumers as well as use certain device consumables as part of their treatments.
20GF Score
Get the complete analysis for NSE:AAKAAR
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:AAKAAR has been successfully added to your 
